Business Wire

Ant Group Appointed by Elevandi as Advisory Committee Member

31.5.2022 09:32:00 EEST | Business Wire | Press release

Share

Ant Group has been appointed as a member on the advisory committee of Elevandi, a company set up by the Monetary Authority of Singapore (MAS) with a mission to foster an open dialogue between the public and private sectors to advance FinTech in the digital economy.

The advisory committee comprises senior leaders from eight organizations ranging from established financial institutions to Tech/FinTech players. Mr. Chen Leiming, Senior Vice President, who is responsible for Ant Group’s international public policy and government affairs, serves as the representative of Ant Group. Mr. Chen also oversees the legal, compliance, AML and privacy functions of Ant Group’s international businesses.

As an advisory committee member, Mr. Chen Leiming will represent Ant Group and involve in providing strategic guidance on:

  1. galvanising global conversations to shape FinTech industry agendas worldwide;
  2. identifying key structural trends and issues shaping the future of financial services; and
  3. fostering an open dialogue between policymakers and FinTech players on Fintech risks and opportunities.

Speaking on the appointment of Ant Group as an advisory committee member, Mr. Sopnendu Mohanty, Chairman of Elevandi’s Board of Directors and Chief FinTech Officer of MAS, said: “Elevandi's mission is to bring together the public and private sector to adopt technology and build the future of finance that is inclusive, impactful and sustainable. We welcome organisations that have shown passion and dedication in harnessing FinTech for the growth and development of the new digital economy to participate as advisory committee members.”

Mr. Chen Leiming, Senior Vice President, Ant Group, said: “It is a great honour to represent Ant Group and contribute to the mission of Elevandi which we share and resonate deeply. At Ant Group, we are committed to leveraging technology and knowledge to provide inclusive services to those unserved and underserved, and contribute to the society through initiatives such as Ant Forest to promote low carbon lifestyle, and 10x1000 Tech for Inclusion to bridge the global digital skills gap."

"We look forward to joining the fellow members of the advisory committee in furthering Elevandi’s efforts on cultivating a more inclusive, green, and sustainable fintech landscape for the future," Mr. Chen said.

As part of Ant Group’s participation in Elevandi, Mr. Douglas Feagin, Senior Vice President for Global Strategic Partnerships and Investments at Ant Group will attend Elevandi’s inaugural Point Zero Forum in Zurich as a speaker. Point Zero Forum is an invite-only, in-person gathering to frame new ideas in Web 3.0 and sustainable finance; develop new regulatory frameworks; and provide access to investment capital.

For more information on Elevandi and the full list of advisory committee members, please visit https://www.elevandi.io/media/company-set-up-by-mas-to-advance-fintech-announces-advisory-committee.

About Ant Group

Ant Group aims to create the infrastructure and platform to support the digital transformation of the service industry. It strives to enable all consumers and small and micro businesses to have equal access to financial and other services that are inclusive, green and sustainable.

Ant Group is the owner and operator of Alipay, the leading digital platform in China serving hundreds of millions of users, and connecting them with merchants and partner financial institutions that offer inclusive financial services and digital daily life services such as food delivery, transport, entertainment, and healthcare.

Ant Group has further introduced Alipay+, which provides global cross-border mobile payments and marketing solutions that connect merchant partners, especially small and medium-sized businesses, with mobile payments and other payment methods, for them to better serve their users and customers from all over the world.

For more information, please visit our website at www.antgroup.com or follow us on Twitter @AntGroup.

About Elevandi

Elevandi is set up by the Monetary Authority of Singapore (MAS) to foster an open dialogue between the public and private sectors to advance FinTech in the digital economy. We work closely with governments, founders, investors, and corporate leaders to drive collaboration, education, and new sources of value at the industry and national levels. Our initiatives have convened over 300,000 people since 2016 to drive the growth of FinTech through events, closed-door roundtables, investor programmes, educational initiatives, and research. ​​

We have built a coordinated set of consequential products that drive activity at the industry, national, regional and global level, which include:

  • Singapore FinTech Festival (2-4 Nov 2022), our annual flagship event for the global FinTech community.
  • Point Zero Forum (21-23 June 2022), our invite only collaboration with the Switzerland government to convene leaders, investors and founders in Zurich.
  • Elevandi Connects (7 July 2022), our programme and initiative to bring together early stage start-ups with leading investors and corporates to maximise commercial success in forging investment deals, co-innovation opportunities, and business partnerships.
  • World FinTech Festival (July-Nov 2022), our partnerships with the public and private sectors in markets around the world.
  • Green Shoots Series, our monthly event meetup which serves as a platform for public and private sector announcements and to discuss critical issues and opportunities in FinTech and the digital economy.
  • Education initiatives, our certificates and mentoring programmes to upskill and reskill the global FinTech community in collaboration with Oxygen by APIX, academic and industry partners.
  • Elevandi Forums, our purpose-driven roundtables aimed at bringing the public and private sectors together to advance developments and issues within the FinTech industry.
  • Elevandi FinTech Insider Report, our reports on digital advancements for the global FinTech industry which synthesise knowledge from our activities with the public and private sectors.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Ant Group
Betty Bai
M: (65) 9183 9108
E: guzhuang.bb@antgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Massive Gaming Secures MGA B2B License to Expand Global iGaming Partnerships23.3.2026 11:13:00 EET | Press release

Massive Gaming (MVG), a global iGaming content provider with headquarters in Australia, has secured a B2B Gaming License from the Malta Gaming Authority (MGA), marking a key milestone in the company’s expansion into regulated international markets. The MGA license enables Massive Gaming to supply its gaming content and solutions to operators licensed under the Malta regulatory framework, strengthening the company’s ability to collaborate with partners across Europe and other regulated jurisdictions. To support its regulatory expansion, Massive Gaming established MVG Malta, a dedicated entity created as part of the licensing process, and which supports the company’s broader strategy to strengthen its presence within the European iGaming ecosystem. Massive Gaming develops its gaming portfolio across three studios - Slot Mart, Whale House and Blitzcrown. All three deliver a range of gaming experiences spanning traditional slot titles, regulated market content and emerging non-traditional

LTM Expands BlueVerse ™ Tech with AppIQ, AgentIQ and FusionIQ to Accelerate AI‑Led Engineering23.3.2026 10:30:00 EET | Press release

LTM – the Business Creativity partner to the world’s largest enterprises, today announced the expansion of BlueVerseTM Tech, its AI‑led engineering platform, with the launch of AppIQ, AgentIQ and FusionIQ—three purpose‑built platforms designed to help enterprises modernize applications, orchestrate AI‑first software delivery, and engineer quality at scale. As software development evolves from human‑only execution to human + intelligent agents, traditional effort‑driven engineering and QA models are increasingly unable to keep pace. These BlueVerseTM platforms embed agentic, engineering‑aware AI across the software development lifecycle (SDLC), enabling enterprises to move faster from legacy complexity to modern, resilient, and high‑quality digital systems. AppIQ — Modernize Legacy Applications, Faster AppIQ applies AI to read and understand legacy codebases, generate documentation, map functional workflows, and produce actionable specifications for forward engineering. What previously

Galderma Receives U.S. FDA Approval for Restylane ® Contour™ for the Correction of Temple Hollowing23.3.2026 08:00:00 EET | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hollowing in patients over the age of 21.1,2 This builds on its previous approvals for cheek augmentation and midface contour deficiencies, helping injectors address volume loss across key structural areas.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260322108467/en/ With the broadest Injectable Aesthetics portfolio in the industry, this follows the recent U.S. approval of Restylane Lyft for augmentation of the chin region, adding to its indications to treat the midface, facial folds and wrinkles, back of hands, and the chin.4,5 Together, these approvals demonstrate Galderma’s ongoing commitment to evolving the versatile Restylane portfolio to deliver personalized, natural-looking outcomes that meet diverse patient needs.1,4,6,7 The volume of the temples can dimi

Paving the Way for Real‑Time Earth Observation: Space Compass and SWISSto12 Sign Contract for First Commercial GEO Optical Data Relay Satellite23.3.2026 06:00:00 EET | Press release

Space Compass Corporation (“Space Compass”) and SWISSto12 SA (“SWISSto12”) announced today that they have executed a procurement contract for the first GEO optical data relay satellite. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320584108/en/ (From Left to Right): Julie Pignon, Legal Counsel, SWISSto12; 倉田 るり子 (Ruriko Kurata), Legal Counsel, Space Compass; 小松 大実 (Hiromi Komatsu), Co-CEO, Space Compass; 田中 良太 (Ryota Tanaka), Engineering Director, Space Compass; Emile de Rijk, CEO, SWISSto12; Fredrik Gustavsson, Chief Financial and Strategy Officer, SWISSto12. This agreement represents a major milestone toward the realization of Space Compass’s optical data relay service. With high-speed, high-capacity optical data relay service, Space Compass aims to transform Earth Observation from just a tracking record into a real-time decision-making tool. For SWISSto12, the contract represents further validation of the company’s a

Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentations at AAD include: Late-Breaking Oral Presentations Hidradenitis Suppurativa Povorcitinib in Patients With Moderate to Severe Hidradenitis Suppurativa: 54-Week Efficacy and Safety Results From the STOP-HS1 & STOP-HS2 Phase 3 Studies (Session: S034 – Late-Breaking Research: Sess

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye